ArticleFoot & ankle orthopaedics2025
Evaluating Clinical Outcomes of Recombinant Human Bone Morphogenetic Protein-2 in the Treatment of Subchondral Plate Damage Associated With Ankle Osteochondral Lesions.
Article in Foot & ankle orthopaedics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cartilage lesions with concomitant subchondral plate damage are challenging pathologies for foot and ankle surgeons. Recent clinical reports suggest that recombinant human bone morphogenetic protein-2 (rhBMP-2) can restore structural integrity of the subchondral plate and promote osseous healing, potentially improving outcomes for cartilage repair procedures. This study seeks to evaluate the complication rate and patient-reported outcomes of rhBMP-2-augmented repair for ankle osteochondral lesions with subchondral involvement. Methods: Patients who received surgical repair with rhBMP-2, extracellular matrix (ECM), and bone marrow aspirate concentrate (BMAC) for the treatment of an ankle osteochondral defect with an associated subchondral damage between January 2023 and September 2024 were retrospectively chart reviewed. Twenty-one patients who fit the criteria were included. All patients completed Patient-Reported Outcomes Measurement Information System (PROMIS) surveys preoperatively and at minimum 1 year postoperatively. Clinical outcomes, postoperative complications, and revision surgery were recorded. Results: The average time from surgery to postoperative survey follow-up was 17.9 (range, 12.0-27.3) months. Average cartilage lesion size was 88.4 (range, 36.0-120) mm Conclusion: Our results suggest that this procedure is an effective treatment with a significant improvement in clinical outcomes and a low complication rate. Level of Evidence: Level IV, case series.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.